AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline

Rhea-AI Summary

AbbVie (NYSE: ABBV) will present extensive oncology pipeline data at the ASCO 2026 Annual Meeting, covering solid tumors and blood cancers.

Highlights include Phase 1 Top1i ADC results in mCRPC, SCLC, PROC and HNSCC, and Phase 1b T‑cell engager data in relapsed/refractory multiple myeloma showing notable objective response rates and manageable safety profiles.

News Market Reaction – ABBV

+0.56%

+0.56% Session close to close

In the May 22 session, ABBV gained 0.56%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights AbbVie’s breadth in oncology, with notable response rates across mCRPC,...

Analysis

This announcement highlights AbbVie’s breadth in oncology, with notable response rates across mCRPC, SCLC, ovarian cancer, head and neck cancer, and R/R multiple myeloma, including a median response duration of 13 months in an etentamig cohort. Recent history shows stronger share reactions to financial results than to scientific meetings, so investors may track how these early data translate into later‑phase trials, regulatory milestones, and eventual revenue contributions alongside AbbVie’s established franchises.

Key Figures

ORR in mCRPC: 45% PSA50 response: 67% PSA90 response: 28% +5 more

8 metrics

ORR in mCRPC 45% ABBV-969 Phase 1, 29 RECIST-evaluable metastatic castration-resistant prostate cancer patients

PSA50 response 67% ABBV-969 Phase 1 active dose levels in mCRPC (≥50% PSA reduction)

PSA90 response 28% ABBV-969 Phase 1 mCRPC patients achieving ≥90% PSA reduction

ORR in SCLC 82% ABBV-706 Phase 1 monotherapy cohort (n=17) at 1.8 mg/kg in second-line SCLC

Etentamig ORR 64% Phase 1b etentamig in 11 R/R multiple myeloma patients post BCMA CAR-T

MRD negativity 67% (2/3) Evaluable etentamig patients with prior BCMA-directed therapy achieving MRD negativity

Median duration of response 13 months Etentamig Phase 1b R/R multiple myeloma cohort

CRS incidence 57% Etentamig-treated patients with cytokine release syndrome (all grade 1–2, no SUD)

Historical Context

5 past events · Latest: May 06 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 06	Conference appearance	Neutral	-0.5%	Announcement of AbbVie fireside chat at Bank of America healthcare conference.
May 05	IBD data update	Positive	-1.0%	Long-term data for risankizumab and upadacitinib in Crohn’s and ulcerative colitis.
May 05	IBD clinical data	Positive	-1.0%	Phase 1 and preclinical data for oral NIM-1324 showing favorable safety and efficacy.
Apr 30	Philanthropic campaign	Positive	+3.6%	Allergan Aesthetics referral-based donations tied to new Allē members in May.
Apr 29	Q1 2026 earnings	Positive	+3.1%	Strong Q1 revenues and raised 2026 adjusted EPS guidance with key portfolio growth.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent scientific and conference news has sometimes seen negative or muted reactions, while earnings and consumer-facing initiatives drew stronger positive moves.

Recent Company History

Over the last month, AbbVie has released several updates across finance, immunology, and corporate events. Q1 2026 results on Apr 29 showed net revenues of $15.002B and a raised adjusted EPS outlook, with shares rising about 3%. A philanthropic aesthetics campaign on Apr 30 also coincided with a roughly 3.6% gain. In contrast, scientific and conference-focused news around IBD and a healthcare conference in early May saw mildly negative reactions. Today’s ASCO 2026 oncology pipeline data fits the pattern of R&D-focused updates following strong financial positioning.

Key Terms

antibody-drug conjugate, topoisomerase i inhibitor, t-cell engager, objective response rate, +4 more

8 terms

antibody-drug conjugate medical

"antibody‑drug conjugate (ADC) platform, including Topoisomerase I inhibitor..."

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

topoisomerase i inhibitor medical

"including Topoisomerase I inhibitor (Top1i)–based ADCs and its T‑cell engager..."

A topoisomerase I inhibitor is a drug that blocks a cellular “untangling” enzyme called topoisomerase I, which cells use to unwind and copy DNA. By preventing that untangling, the drug can stop rapidly dividing cells (like cancer cells) from reproducing and trigger cell death—think of jamming a winch that keeps a rope from being wound correctly. Investors care because such drugs can be transformative if safe and effective, but their value depends heavily on clinical trial results, side‑effect profiles, regulatory approval and patent protection.

t-cell engager medical

"Top1i)–based ADCs and its T‑cell engager (TCE) portfolio."

A T-cell engager is a type of medicine designed to help the body's immune system attack cancer cells more effectively. It works by acting like a bridge that brings immune cells (T-cells) close to cancer cells, prompting a targeted attack. For investors, T-cell engagers are significant because they represent innovative treatments that could lead to new growth opportunities in the healthcare and biotech sectors.

objective response rate medical

"demonstrated a confirmed objective response rate (ORR) of 45% among 29 patients..."

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

minimal residual disease medical

"Minimal residual disease (MRD) negativity was observed in 67% (2/3) of evaluable..."

Minimal residual disease (MRD) is the tiny number of cancer cells that remain in the body after treatment, often too few to show up on standard scans but detectable with very sensitive tests. For investors, MRD is important because it predicts the risk of relapse and can determine whether a therapy is seen as effective, influences regulatory and reimbursement decisions, and affects the size and timing of a drug’s market opportunity—like spotting the last weeds that can make a garden regrow if not removed.

cytokine release syndrome medical

"all cytokine release syndrome (CRS) reported (57%) were grade 1 and 2."

An intense immune overreaction in which the body's defense system releases a large surge of signaling proteins, causing fever, low blood pressure, breathing trouble or organ stress; imagine the immune system's alarm going into overdrive and flooding the body with emergency responders. Investors care because this side effect can slow or block regulatory approval, increase clinical trial costs and liabilities, limit how widely a therapy can be used, and therefore affect a drug's market value and sales potential.

circulating tumor dna medical

"comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer."

Fragments of DNA shed by cancer cells into the bloodstream that act like tiny fingerprints of a tumor; they can be detected with a blood test rather than a biopsy. Investors care because circulating tumor DNA (ctDNA) enables faster, lower-cost ways to detect disease, track treatment response, identify emerging resistance and enroll patients in trials—factors that can materially affect the commercial prospects of diagnostics and therapeutics.

first-in-human medical

"A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics..."

A first-in-human study is the initial test of a new drug, medical device, or therapy in people to check safety, side effects and appropriate dosing. It matters to investors because it marks a major development milestone: successful early human testing can reduce scientific and regulatory uncertainty, much like moving a prototype from the workshop to a real-world test drive, and often affects a company’s valuation and funding prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

 - Data from novel Top1i ADC and T-cell engager platforms highlight potential within solid tumors and blood cancers, including oral presentations in prostate cancer, small cell lung cancer, platinum-resistant ovarian cancer and multiple myeloma - 

NORTH CHICAGO, Ill., May 21, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology pipeline. The data will be shared through multiple oral presentations and posters spanning solid tumors and blood cancer indications.

Collectively, these presentations highlight AbbVie's continued focus on attacking cancer from inside and outside the cell, supported by sustained investment in its expanding antibody‑drug conjugate (ADC) platform, including Topoisomerase I inhibitor (Top1i)–based ADCs and its T‑cell engager (TCE) portfolio.

"Our oncology pipeline is intentionally designed to address the complexity and heterogeneity of cancer biology through a diversified portfolio of differentiated therapies spanning multiple modalities," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology. "The data we are presenting at ASCO reflect the strength of this strategy, including continued momentum with our ADC programs in solid tumors and validation of immune-based approaches, such as etentamig, being investigated as a next-generation TCE in multiple myeloma. These results underscore our commitment to advancing assets with distinct scientific approaches aimed to address critical unmet patient needs." 

Key findings presented include:

Data from AbbVie's Top1i ADCs Across Solid Tumors:

• Metastatic castration-resistant prostate cancer (mCRPC): A first-in-human Phase 1 study (NCT06318273) evaluating ABBV-969, a potential first-in-class bispecific ADC targeting PSMA/STEAP1, in heavily pretreated patients with mCRPC, demonstrated a confirmed objective response rate (ORR) of 45% among 29 patients with RECIST-evaluable disease. At active dose levels, 67% of patients achieved at least a 50% reduction in prostate-specific antigen (PSA50), with 28% achieving PSA90 responses. The safety profile was manageable in heavily pretreated patients with mCRPC.¹ Additional findings to be presented at the meeting.

• Small cell lung cancer (SCLC): In Phase 1 data (NCT05599984) of ABBV-706 (SEZ6-directed ADC) in the monotherapy cohort (n=17), SCLC patients receiving ABBV-706 at the recommended Phase 3 dose of 1.8 mg/kg as a second-line therapy achieved an objective response rate (ORR) of 82%— promising data in a disease where prognosis remains poor. The safety profile was comparable with previously reported data.² Additional findings and updated data will be presented at the meeting. The findings support continued evaluation of ABBV-706 in SCLC.

• Platinum-resistant ovarian cancer (PROC) and head and neck squamous cell carcinoma (HNSCC): Data from a Phase 1 basket study of Telisotuzumab adizutecan (Temab-A), a next-generation c-Met–directed ADC, demonstrated antitumor activity of Temab-A monotherapy in biomarker unselected PROC (NCT06084481) and HNSCC (NCT06084481) patients.^3,4
  • Additional observations in c-Met selected patients, to be presented at the meeting, highlight the potential of Temab-A in this population.^3,4
  • These new data support the potential of Temab-A across an expanding range of solid tumors and patient populations, including previously presented data in lung, colorectal and gastric cancers and across patients with MET-amplification and increased c-Met expression.

• Relapsed/refractory multiple myeloma (R/R MM): Data from a Phase 1b study of etentamig (NCT05650632), being investigated as a next-generation B-cell maturation antigen (BCMA) x CD3 T-cell engager, as monotherapy in a cohort of heavily pre-treated BCMA-exposed R/R MM patients will be presented at the meeting.
  • Etentamig is an investigational BCMA and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain.
  • The data showed that among patients (n=11) that proceeded to etentamig after BCMA-directed CAR-T in the prior line of therapy, an ORR of 64% was achieved. Minimal residual disease (MRD) negativity was observed in 67% (2/3) of evaluable patients who received BCMA-directed therapy in the prior line of therapy. The median duration of response was 13 months. No new safety signals were observed. Despite no step-up dosing (SUD) in this cohort, all cytokine release syndrome (CRS) reported (57%) were grade 1 and 2.⁵ Additional findings to be presented at the meeting.

Further information on AbbVie clinical trials is available at https://www.clinicaltrials.gov/.

Additional details on key presentations are available below, and the full ASCO Annual Meeting 2026 abstracts are available here.

Title	Date/Time	Session	Abstract Number
Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)-targeted therapy.	Friday, May 29   5:09-5:21 PM CDT	Oral Presentation   Oral Abstract Session   Hematologic Malignancies— Plasma Cell Dyscrasia	7508
Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein-targeting antibody- drug conjugate: Results from patients with platinum-resistant ovarian/primary epithelial/fallopian tube cancer (PROC).	Saturday, May 30   8:42-8:48 AM CDT	Rapid Oral Abstract Session   Gynecologic Cancer	5514
A phase 2 randomized study comparing telisotuzumab adizutecan monotherapy with standard of care in patients with post-adjuvant circulating tumor DNA-positive colorectal cancer.	Saturday, May 30   9:00 AM- 12:00 PM CDT	Poster Board: 447a   Poster Session   Gastrointestinal Cancer—Colorectal and Anal	TPS3688
A Phase 2 study of telisotuzumab adizutecan (ABBV-400; Temab-A) in patients with advanced solid tumors harboring MET amplification.	Saturday, May 30   1:30-4:30 PM CDT	Poster Board: 293a   Poster Session    Developmental Therapeutics— Molecularly Targeted Agents and Tumor Biology	TPS3157
Phase 1 basket study of telisotuzumab adizutecan (ABBV- 400, Temab-A), a c-Met protein- targeting antibody-drug conjugate: Results from patients with head and neck squamous cell carcinoma (HNSCC).	Saturday, May 30   1:30-4:30 PM CDT	Poster Board: 484   Poster Session    Head and Neck Cancer	6027
Telisotuzumab adizutecan (Temab-A) plus osimertinib (osi) as 1L treatment for unresectable/metastatic NSCLC.	Sunday, May 31   9:00 AM- 12:00 PM CDT	Poster Board: 451a   Poster Session    Lung Cancer— Non-Small Cell Metastatic	TPS8663
Impact of MET amplification (amp) on telisotuzumab vedotin (Teliso-V) efficacy and safety in 2L+ non-squamous (NSQ) EGFR wild-type (WT) NSCLC with c-Met protein overexpression (OE).	Sunday, May 31   9:00 AM- 12:00 PM CDT	Poster Board: 314   Poster Session   Lung Cancer— Non-Small Cell Metastatic	8524
AndroMETa-Lung-713: A phase 2/3 study of telisotuzumab adizutecan (ABBV-400, Temab-A) vs standard of care (SOC) in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC).	Sunday, May 31   9:00 AM- 12:00 PM CDT	Poster Board: 450a   Poster Session   Lung Cancer— Non-Small Cell Metastatic	TPS8661
SEZanne: A phase 2 randomized, open-label, multicenter study to evaluate the optimal dose, safety, and efficacy of ABBV-706 in combination with atezolizumab (atezo) versus standard of care (SOC) in patients (pts) with previously untreated extensive- stage (ES) small cell lung cancer (SCLC).	Sunday, May 31   9:00 AM- 12:00 PM CDT	Poster Board: 603a   Poster Session   Lung Cancer—Non- Small Cell Local- Regional/Small Cell/Other Thoracic Cancers	TPS8135
A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC).	Sunday, May 31   4:42-4:48 PM CDT	Rapid Oral Abstract Session   Genitourinary Cancer—Prostate, Testicular, and Penile	5014
A single-arm, phase 2 study of neoadjuvant mirvetuximab soravtansine and carboplatin for FRα-expressing advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer (M25-231; NCT06890338; GOG- 3115).	Monday, June 1   9:00 AM- 12:00 PM CDT	Poster Board: 296b   Poster Session   Gynecologic Cancer	TPS5633
ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC).	Monday, June 1   3:39-3:51 PM CDT	Oral Presentation   Oral Abstract Session   Lung Cancer—Non- Small Cell Local- Regional/Small Cell/Other Thoracic Cancers	8008
Phase 1, first-in-human (FIH) study evaluating safety and efficacy of ABBV-706: Results from patients with high-grade central nervous system (CNS) tumors.	Monday, June 1   1:30-4:30 PM CDT	Poster Board: 406   Poster Session   Central Nervous System Tumors	2041
A US-based, retrospective, observational study of biomarker testing patterns across lines of therapy in patients with metastatic colorectal cancer.	N/A	Publication Only   Gastrointestinal Cancer – Colorectal and Anal	e15526
Timing of biomarker testing and associated clinical outcomes in ovarian cancer patients: A retrospective study.	N/A	Publication Only   Gynecologic Cancer	e17574
Real-world (RW) characteristics and outcomes in platinum- resistant ovarian cancer (PROC) patients treated with mirvetuximab soravtansine (MIRV) monotherapy or single- agent chemotherapy (CTx).	N/A	Publication Only   Gynecologic Cancer	e17606

Telisotuzumab adizutecan (Temab-A), etentamig, ABBV-969, and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.

U.S. Prescribing Information for AbbVie Medicines

Please see full Prescribing Information for ELAHERE™ (mirvetuximab soravtansine-gynx)
Please see full Prescribing Information for EMRELIS™ (telisotuzumab vedotin-tllv)
Please see full Prescribing Information for EPKINLY^® (epcoritamab -bysp)

About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube. 

About AbbVie in Oncology
AbbVie is committed to elevating standards of care and bringing transformative therapies to patients worldwide living with difficult-to-treat cancers. We are advancing a dynamic pipeline of investigational therapies across a range of cancer types in both blood cancers and solid tumors. We are focusing on creating targeted medicines that either impede the reproduction of cancer cells or enable their elimination. We achieve this through various, targeted treatment modalities and biology interventions, including small molecule therapeutics, antibody-drug conjugates (ADCs), immuno-oncology-based therapeutics, multispecific antibody and novel CAR-T platforms. Our dedicated and experienced team joins forces with innovative partners to accelerate the delivery of potential breakthrough medicines.

Today, our expansive oncology portfolio comprises approved and investigational treatments for a wide range of blood cancers and solid tumors. We are evaluating more than 35 investigational medicines in multiple clinical trials across some of the world's most widespread and debilitating cancers. As we work to have a remarkable impact on people's lives, we are committed to exploring solutions to help patients obtain access to our cancer medicines. For more information, please visit http://www.abbvie.com/oncology.

Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry, the impact of global macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs, and other uncertainties and risks associated with global business operations. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2025 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its Quarterly Reports on Form 10-Q and in other documents that AbbVie subsequently files with the Securities and Exchange Commission that update, supplement or supersede such information. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. 

References:

1. Dorff T, Peer A, Sharma M, et al. A phase 1, first-in-human (FIH) study evaluating the safety, pharmacokinetics, and efficacy of ABBV-969 in patients with metastatic castration-resistant prostate cancer (mCRPC). Abstract 5014presented at the American Society of Clinical Oncology Annual Meeting, 2026. Chicago, Illinois.
2. Byers L, Cho B, Cooper A, et al. ABBV-706 as monotherapy and in combination with budigalimab in patients with relapsed/refractory (R/R) small cell lung cancer (SCLC). Abstract 8008 presented at the American Society of Clinical Oncology Annual Meeting, 2026. Chicago, Illinois.
3. Fleming G, Kurnit K, Pelster M, et al. Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein-targeting antibody-drug conjugate: Results from patients with platinum-resistant ovarian/primary peritoneal/fallopian tube cancer (PROC). Abstract 5514 presented at the American Society of Clinical Oncology Annual Meeting, 2026. Chicago, Illinois.
4. Villaflor V, Harding J, Mahadevan D, et al. Phase 1 basket study of telisotuzumab adizutecan (Temab-A, ABBV-400), a c-Met protein-targeting antibody-drug conjugate: Results from patients with head and neck squamous cell carcinoma (HNSCC). Abstract 6027 presented at the American Society of Clinical Oncology Annual Meeting, 2026. Chicago, Illinois.
5. Chhabra S, Searle E, Popat R, et al. Etentamig in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with prior exposure to B-cell maturation antigen (BCMA)-targeted therapy. Abstract 7508 presented at the American Society of Clinical Oncology Annual Meeting, 2026. Chicago, Illinois.

Contacts:
Media:	Investors:
Sourojit (Jit) Bhowmick, Ph.D.	Liz Shea
jit.bhowmick@abbvie.com	liz.shea@abbvie.com

View original content:https://www.prnewswire.com/news-releases/abbvie-announces-new-data-at-asco-2026-demonstrating-breadth-and-momentum-across-its-next-generation-oncology-pipeline-302779632.html

SOURCE AbbVie

FAQ

What oncology pipeline data will AbbVie (NYSE: ABBV) present at ASCO 2026?

AbbVie will present new data across its next-generation oncology pipeline at ASCO 2026. According to AbbVie, these include multiple oral and poster presentations on antibody-drug conjugates and T-cell engagers in prostate, lung, ovarian, head and neck cancers, and multiple myeloma.

What did AbbVie report about ABBV-969 in metastatic castration-resistant prostate cancer at ASCO 2026?

AbbVie reported Phase 1 data for ABBV-969 in metastatic castration-resistant prostate cancer. According to AbbVie, among 29 RECIST-evaluable patients, the confirmed objective response rate was 45%, with 67% achieving PSA50 reductions and 28% achieving PSA90 responses, alongside a manageable safety profile.

How effective was ABBV-706 for small cell lung cancer in AbbVie’s ASCO 2026 data?

AbbVie shared Phase 1 results for ABBV-706 in small cell lung cancer at ASCO 2026. According to AbbVie, SCLC patients receiving 1.8 mg/kg second-line monotherapy achieved an objective response rate of 82%, with a safety profile comparable to previously reported data, supporting continued evaluation.

What ASCO 2026 results did AbbVie announce for Temab-A (telisotuzumab adizutecan) in ovarian and head and neck cancers?

AbbVie announced Phase 1 basket study results for Temab-A in PROC and HNSCC. According to AbbVie, Temab-A monotherapy demonstrated antitumor activity in biomarker-unselected patients, with additional observations in c-Met–selected patients suggesting potential across multiple solid tumors and MET-amplified or c-Met–overexpressing populations.

What were the key etentamig multiple myeloma findings AbbVie will present at ASCO 2026?

AbbVie will present Phase 1b data for etentamig in relapsed/refractory multiple myeloma. According to AbbVie, among 11 patients treated after BCMA-directed CAR-T, the objective response rate was 64%, median duration of response 13 months, and 67% MRD negativity among evaluable patients, with only grade 1–2 CRS.

Are AbbVie’s Temab-A, etentamig, ABBV-969, and ABBV-706 approved therapies as of ASCO 2026?

These AbbVie assets are investigational medicines and not approved by health authorities worldwide. According to AbbVie, their safety and efficacy remain under evaluation in ongoing clinical studies, with data being presented at ASCO 2026 to inform further development across multiple tumor types.